Dimensional Fund Advisors LP Grows Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Dimensional Fund Advisors LP lifted its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 60.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 181,929 shares of the company's stock after purchasing an additional 68,200 shares during the period. Dimensional Fund Advisors LP's holdings in Takeda Pharmaceutical were worth $2,409,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in TAK. Farther Finance Advisors LLC raised its position in Takeda Pharmaceutical by 123.6% in the fourth quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock worth $47,000 after acquiring an additional 1,976 shares during the period. Crowley Wealth Management Inc. bought a new stake in Takeda Pharmaceutical in the fourth quarter worth about $52,000. Cromwell Holdings LLC bought a new stake in Takeda Pharmaceutical in the fourth quarter worth about $61,000. Venturi Wealth Management LLC raised its position in shares of Takeda Pharmaceutical by 554.7% in the fourth quarter. Venturi Wealth Management LLC now owns 5,028 shares of the company's stock valued at $67,000 after purchasing an additional 4,260 shares during the period. Finally, Lindbrook Capital LLC raised its position in shares of Takeda Pharmaceutical by 65.0% in the fourth quarter. Lindbrook Capital LLC now owns 5,151 shares of the company's stock valued at $68,000 after purchasing an additional 2,029 shares during the period. 9.17% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley raised shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research report on Wednesday, April 2nd.

Takeda Pharmaceutical Stock Performance

Shares of NYSE TAK traded up $0.11 during midday trading on Friday, hitting $14.11. The company's stock had a trading volume of 1,136,705 shares, compared to its average volume of 1,918,399. The stock has a fifty day moving average price of $14.76 and a 200 day moving average price of $14.00. Takeda Pharmaceutical Company Limited has a one year low of $12.58 and a one year high of $15.43. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $44.88 billion, a price-to-earnings ratio of 35.26, a P/E/G ratio of 0.24 and a beta of 0.26.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.16 EPS for the quarter, missing the consensus estimate of $0.24 by ($0.08). The firm had revenue of $7.34 billion for the quarter, compared to analysts' expectations of $8.02 billion. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. On average, research analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.